Alkermes Contract Pharma Services has a unique platform of validated drug delivery technologies to offer our partners - from oral controlled release, delayed release and pulsatile release drug delivery systems as well as solutions for poorly water soluble compounds.
We have a complete range of capabilities from formulation development through to commercial scale manufacture in modern facilities. Our drug delivery technologies are supported by robust patent estate of almost 1,500 patents and pending applications worldwide.
It is estimated that in excess of 40% of compounds in development suffer from poor solubility, making them difficult to develop and resulting in a significant number of potentially beneficial compounds being discarded in development each year. Alkermes Contract Pharma Services bioavailability enhancement technology platform helps address this key problem for the pharmaceutical industry.
Improved bioavailability can bring one or more of the following benefits for a fast, elegant solution for poorly water soluble compounds:
More Bioavailability Enhancement Technology information
To find out if your drug candidate would benefit from our expertise in bioavailability enhancement please contact us.
Alkermes Contract Pharma Services has developed a range and depth of solid oral dosage technologies unrivaled in drug product development. We have been applying our range of technology approaches to help overcome many of the technical difficulties that have been encountered by pharmaceutical companies.
The OCR technology platform can bring one or more of the following benefits for new and existing drug products:
More Oral Control Release Technology information
To find out if your drug candidate would benefit from our expertise in oral controlled release please contact us.
You are now leaving Alkermes.com.
